Frost & Sullivan: The Anticipated Launch of Innovative Drugs Will Transform the Latin American Diabetes Therapeutics Market

Description

Frost & Sullivan: The Anticipated LaunchFrost & Sullivan: The Anticipated Launch of Innovative Drugs Will Transform the Latin American Diabetes Therapeutics Market PR Newswire BUENOS AIRES, Argentina, Feb. 18, 2014 - To widen market potential, pharma companies must roll out long-lasting therapies that delay or prevent disease progression The Latin American diabetes therapeutics market will experience major changes within the next three years due to the launch of innovative drugs that include three long-acting insulins and four non-insulin treatments. Nevertheless, pharmaceutical companies should continue their research to develop treatments that can restore beta-cell function and thereby postpone or prevent disease progression – areas that even newer therapies do not address. New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), Trends, Opportunities, and Challenges for the Latin American Diabetes Therapeutics Market, expects the diabetes therapeutics market to grow due to the rising prevalence of diabetes in the region. Improved awareness among patients on the importance of early diagnosis and treatment of diabetes will ensure steady market growth in the next five years. The research covers non-insulin and insulin therapeutics. Currently, type 2 diabetic patients with metabolic syndrome need to separately administer drugs for each diabetes, arterial hypertension, and hyperlipidemia.

Informations

• Publié par: frost-sullivan
• Publié le: 18 février 2014
• Nombre de lectures: 1
• Langue: English

Extrait

Frost & Sullivan: The Anticipated Launch of Innovative Drugs Will Transform the Latin American Diabetes Therapeutics Market

PR Newswire

BUENOS AIRES, Argentina, Feb. 18, 2014

- To widen market potential, pharma companies must roll out long-lasting therapies that delay or prevent disease progression

The Latin American diabetes therapeutics market will experience major changes within the next three years due to the launch of innovative drugs that include three long-acting insulins and four non-insulin treatments. Nevertheless, pharmaceutical companies should continue their research to develop treatments that can restore beta-cell function and thereby postpone or prevent disease progression – areas that even newer therapies do not address.